ASCO GI 2024 | MATTERHORN: improved pCR with the use of durvalumab + FLOT in resectable GC/GEJC

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the MATTERHORN study (NCT04592913), which aimed to enhance perioperative therapy for resectable gastric/gastroesophageal junction cancer (GC/GEJC). Randomizing participants to receive either durvalumab + FLOT or placebo + FLOT, the study revealed improved pathologic complete response (pCR) rates with durvalumab + FLOT across regions. Despite baseline variations, the addition of durvalumab consistently enhanced pCR compared to placebo. Ongoing for event-free survival, MATTERHORN suggests the potential of durvalumab + FLOT in GC/GEJC treatment. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.